Aldactone is used for conditions involving excess aldosterone, fluid retention, high blood pressure, or heart failure. It contains spironolactone, a potassium-sparing diuretic that removes sodium and…
Aldactone is used for conditions involving excess aldosterone, fluid retention, high blood pressure, or heart failure. It contains spironolactone, a potassium-sparing diuretic that removes sodium and water while reducing potassium loss; the amount and frequency of use are agreed with a doctor or pharmacist.
Aldactone contains spironolactone, a mineralocorticoid receptor antagonist and potassium-sparing diuretic. The amount used and how often it is taken depend on the purpose of treatment and are agreed with a doctor or pharmacist.
Spironolactone is also available as a generic form. A generic product contains the same active substance and is used for the same pharmacological purposes, while inactive ingredients and tablet appearance may differ between manufacturers.
The dose and frequency depend on the purpose of treatment and are agreed with a doctor or pharmacist. Aldactone tablets are taken by mouth, with the regimen adjusted to the clinical indication and laboratory results.
Common practical principles include:
Aldactone treatment may continue for weeks, months, or longer, depending on the diagnosis. Blood pressure, body weight, swelling, kidney function, sodium, and potassium can all influence dose decisions. Follow-up appointments help assess whether the regimen remains suitable. Laboratory results may prompt a dose change. Report new or worsening symptoms before changing treatment yourself.
Aldactone contains spironolactone, a mineralocorticoid receptor antagonist and potassium-sparing diuretic. The amount used and how often it is taken depend on the purpose of treatment and are agreed with a doctor or pharmacist.
Spironolactone is also available as a generic form. A generic product contains the same active substance and is used for the same pharmacological purposes, while inactive ingredients and tablet appearance may differ between manufacturers.
Aldactone is prescribed for cardiovascular, renal, hepatic, and endocrine conditions. It is not suitable for self-directed treatment of swelling or blood pressure because potassium and kidney function can change without obvious early symptoms.
Spironolactone blocks the action of aldosterone. Aldosterone normally signals the kidneys to retain sodium and water while excreting potassium. Blocking this signal increases sodium and water excretion and reduces potassium wasting. The result is less fluid accumulation without the same potassium loss seen with some other diuretics.
Aldactone is used when aldosterone activity contributes to fluid retention, raised blood pressure, or cardiovascular strain. The United States Food and Drug Administration recognises spironolactone for several indications, while local prescribing information and Medsafe guidance determine use in New Zealand. [1]
| Clinical use | Treatment objective | Main pharmacological effect |
|---|---|---|
| Heart failure | Reduce fluid burden and support cardiovascular treatment | Aldosterone blockade with potassium conservation |
| Oedema and fluid retention | Reduce excess sodium and water | Increased urinary sodium and water excretion |
| Hypertension | Lower blood pressure in selected patients | Reduced fluid volume and aldosterone-mediated vascular effects |
| Primary hyperaldosteronism | Control excess aldosterone activity | Mineralocorticoid receptor blockade |
Heart failure can stimulate persistent aldosterone activity, which promotes sodium retention, fluid accumulation, and cardiac remodelling. Spironolactone addresses that hormonal pathway and may be used alongside other heart-failure medicines.
Oedema may occur with heart, liver, or kidney disease. Aldactone can reduce swelling by increasing sodium and water excretion, although the appropriate regimen depends on the underlying diagnosis and kidney function.
Primary hyperaldosteronism is an endocrine disorder in which the adrenal glands produce too much aldosterone. This can lead to hypertension and low potassium. Spironolactone counteracts aldosterone while the underlying cause is assessed.
Several mistakes can reduce benefit or increase risk:
A common misunderstanding is that every diuretic lowers potassium. Spironolactone has the opposite tendency, so potassium monitoring remains relevant even when another diuretic is taken at the same time.
Aldactone is not suitable for everyone. It is contraindicated in Addison’s disease, also called primary adrenal insufficiency, because aldosterone deficiency is already present and spironolactone can worsen the mineralocorticoid imbalance.
Formal contraindications include:
Important interactions include ACE inhibitors such as lisinopril, angiotensin-receptor blockers such as losartan, potassium supplements, potassium-containing salt substitutes, and some other medicines affecting the renin–angiotensin–aldosterone system. Non-steroidal anti-inflammatory drugs, including ibuprofen and high-dose aspirin, can reduce kidney blood flow and weaken diuretic effects while increasing renal and potassium risks.
Lithium toxicity can also become more likely when kidney handling of lithium changes. Digoxin interpretation may be affected by electrolyte changes. Provide the prescriber or pharmacist with a complete list of prescription medicines, over-the-counter products, and supplements before treatment begins.
This medication is not for you if you have:
Extra caution is required with diabetes, chronic kidney disease, liver disease, low blood pressure, dehydration, and a history of electrolyte abnormalities. Older adults may be more vulnerable to kidney function changes and high potassium.
It is not appropriate during pregnancy because anti-androgenic effects may harm a developing male foetus.
Aldactone’s most important laboratory risk is hyperkalaemia, meaning an abnormally high blood potassium level. The risk rises with kidney impairment, diabetes with renal involvement, dehydration, older age, and combination treatment with medicines that also raise potassium. The EMA describes potassium monitoring as a central part of safe spironolactone use. [2]
Possible adverse effects include:
Gynecomastia is enlargement of breast tissue in men. It occurs because spironolactone affects androgen and progesterone pathways as well as aldosterone receptors. The likelihood can increase with prolonged treatment or higher exposure. Report persistent breast tenderness, a new lump, or troublesome enlargement for clinical assessment.
Hyperkalaemia can cause muscle weakness, unusual fatigue, tingling, palpitations, or abnormal heart rhythms. Symptoms may be absent, which is why a blood test can be more useful than waiting for warning signs.
The risk of dehydration rises when Aldactone is combined with vomiting, diarrhoea, heavy sweating, or inadequate fluid intake. Excessive fluid restriction is also unhelpful unless it has been prescribed for heart failure or another specific condition.
Aldactone is selected for its aldosterone-blocking and potassium-sparing properties. Other medicines may remove more fluid, lower blood pressure through another pathway, or provide more selective aldosterone blockade.
| Treatment | Main action | Typical clinical distinction |
|---|---|---|
| Aldactone — spironolactone | Blocks aldosterone and conserves potassium | Useful when aldosterone activity, heart failure, or hyperaldosteronism is central |
| Furosemide — also sold as Lasix | Loop diuretic that increases sodium and water loss | Stronger fluid removal, with greater risk of low potassium and dehydration |
| Eplerenone | More selective mineralocorticoid receptor antagonist | May cause fewer hormone-related effects, while still raising potassium risk |
Furosemide is often used when rapid or substantial fluid removal is needed. It can lower potassium, magnesium, and sodium, so its monitoring profile differs from spironolactone.
Eplerenone acts on the same broad hormonal pathway but is more selective than spironolactone. It may be considered when breast tenderness, gynecomastia, or menstrual effects become problematic. It still requires attention to potassium and kidney function.
Lisinopril and losartan lower blood pressure through the renin–angiotensin system rather than acting as conventional diuretics. They may be combined with spironolactone in selected heart-failure or hypertension regimens, but the combination can raise potassium and requires laboratory monitoring.
Spironolactone may interact with potassium supplements, aspirin, and ibuprofen. Low-dose aspirin may be used for specific cardiovascular reasons, but regular or high-dose use should be reviewed because non-steroidal anti-inflammatory medicines can affect kidney function and fluid balance.
In clinical practice, doctors usually judge spironolactone by more than one outcome. Blood pressure, swelling, breathlessness, weight, kidney function, potassium, and symptoms such as breast tenderness may all influence the next decision.
A physician will often regard potassium as the key early safety marker. Stable kidney function does not guarantee stable potassium if another medicine is added, dehydration develops, or the dose changes.
The benefit is often strongest when aldosterone activity is genuinely contributing to the condition. A person taking Aldactone for heart failure may notice less swelling or easier breathing, while someone treated for acne or androgenic symptoms may need a longer period before visible changes appear.
One practical issue is that increased urination may be most noticeable after starting treatment or after a dose adjustment. Planning the dose earlier in the day can reduce inconvenience, but the prescribed schedule should remain the priority.
Many people take spironolactone earlier in the day because it can increase urination and disturb sleep when taken late. The correct schedule depends on the prescribed regimen and whether it is combined with another diuretic. Medsafe medicine-safety information supports consistent dosing and monitoring for dizziness, dehydration, and electrolyte changes. Guidance in 2025 and 2026 continues to favour practical timing that supports adherence without altering the prescribed amount.
Avoid potassium supplements and potassium-containing salt substitutes unless they have been specifically prescribed. Regular activity can support cardiovascular health, but strenuous exercise during dehydration, vomiting, diarrhoea, or heavy sweating can increase kidney stress. The World Health Organization's 2020 guidance links cardiovascular risk reduction with appropriate physical activity, dietary patterns, and blood-pressure management; these measures complement rather than replace spironolactone treatment. [3]
Urgent assessment is needed for fainting, severe weakness, a slow or irregular heartbeat, chest pain, severe breathlessness, confusion, or marked muscle weakness. These symptoms can signal serious potassium disturbance, dehydration, kidney problems, or worsening heart failure. Seek prompt medical help for facial swelling, tongue swelling, or difficulty breathing because these may indicate a serious allergic reaction. The EMA's 2019 product information identifies hyperkalaemia and renal impairment as clinically significant risks requiring action rather than routine observation.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
I was prescribed it for fluid retention and noticed that my socks left less of a mark after the first couple of weeks. I had to plan bathroom trips more carefully in the morning. My blood test was normal, so the treatment continued.
Invercargill About eight weeks 28 Oct 2026The first month was uneven, with some dizziness when I stood up quickly. By around three months my skin was calmer, although I still had occasional breakouts. I found taking it earlier in the day easier.
Masterton About three months 3 Nov 2026The swelling in my ankles improved, but I felt tired after the dose was increased. The clinic repeated my kidney and potassium tests, then adjusted the plan. The tiredness settled, though the medicine was not something I could manage casually.
Levin Several weeks 6 Oct 2026I noticed more urination and one episode of light-headedness when I had not eaten much. I was told to avoid potassium salt substitutes and to report stomach illness. The routine became manageable after that.
Gisborne Several months 16 Oct 2026
